Skip to main content
Quest Diagnostics

Evaluation of Heparin-induced Thrombocytopenia Before and during the COVID-19 Pandemic at a US National Reference Laboratory

ISTH 2021 Congress: International Society on Thrombosis and Haemostasis Virtual Congress
Virtual [in-persin conference canceled] July 17, 2021

Evaluation of Heparin-induced Thrombocytopenia Before and during the COVID-19 Pandemic at a US National Reference Laboratory

Authors: E. Wong, L. Worfolk, L. Noh, W. Wu, M. Sahud, F. Racke, J. Dlott

Specialties: Infectious Disease, COVID-19, Oncology, Hematology, Hemostasis, Thrombosis, 

Download key summary

Related content

Publication
Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations
Conference Presentation
Heparin-Induced Thrombocytopenia Testing: ELISA Based Anti-Platelet Factor 4 Polyspecific and IgG-Specific Antibody Detection Assays Compared to the Unfractionated Heparin Serotonin Release Assay
Test FAQ
Anti PF4 and Serotonin Release Assay SRA for Diagnosing Heparin induced Thrombocytopenia Thrombosis HIT HITT
Conference Presentation
Concordance of Low Molecular Weight and Unfractionated Heparin Serotonin Release Assays

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.